Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data

Chen, Jian; Xia, Yu-Jian; Liu, Tian-Yu; Lai, Yuan-Hui; Yu, Ji-Shang; Zhang, Tian-Hao; Ooi, Shiyin; He, Yu-Long

doi:10.1186/s12885-021-08249-x

Table 1 Demographics and clinicopathologic characteristics of patients with Siewert type II/III AEG

From: Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data

Variable	Training cohort (n = 203)		Validation-1 cohort (n = 88)		Validation-2 cohort (n = 105)
Variable	n	%	n	%	n	%
Gender
Male	159	78.33	62	70.45	86	81.90
Female	44	21.67	26	29.55	19	18.10
Age (year)
≤ 40	9	4.43	2	2.27	3	2.86
41–50	15	7.39	8	9.09	5	4.76
51–60	60	29.56	16	18.18	20	19.05
> 60	119	58.62	62	70.45	77	73.33
Family history of cancer
No	175	86.21	76	86.36	94	89.52
Yes	28	13.79	12	13.64	11	10.48
Blood transfusion
No	143	70.44	65	73.86	81	77.14
< 500 mL	25	12.32	11	12.50	10	9.52
500-1000 mL	25	12.32	10	11.36	7	6.67
> 1000 mL	10	4.93	2	2.27	7	6.67
Siewert type
II	119	58.62	49	55.68	64	60.95
III	84	41.38	39	44.32	41	39.05
Organ invasion
Absence	147	72.41	62	70.45	79	75.24
Presence	56	27.59	26	29.55	26	24.76
Serosal infiltration
S0	49	24.14	22	25.00	16	15.24
S1	57	28.08	28	31.82	38	36.19
S2	69	33.99	24	27.27	39	37.14
S3	28	13.79	14	15.91	12	11.43
Borrmann type
I	12	5.91	9	10.23	6	5.71
II	35	17.24	30	34.09	25	23.81
III	138	67.98	44	50.00	66	62.86
IV	18	8.87	5	5.68	8	7.62
PRM
< 3 cm	12	5.91	6	6.82	10	9.52
3-5 cm	148	72.91	72	81.82	87	82.86
> 5 cm	43	21.18	10	11.36	8	7.62
DRM (cm)
Median	12		15		15
Range	0–30		0–35		0–30
pTNM stage
I	13	6.40	12	13.64	14	13.33
II	46	22.66	19	21.59	20	19.05
III	116	57.14	53	60.23	64	60.95
IV	28	13.79	4	4.55	7	6.67
Grade of differentiation
Well	4	1.97	2	2.27	0	0.00
Moderate	62	30.54	29	32.95	27	25.71
Poor	137	67.49	57	64.77	78	74.29
Complications
0-I	166	81.77	74	84.09	78	74.29
II-V	37	18.23	14	15.91	27	25.71
PLN
Median	3		2		3
Range	0–54		0–30		0–46
LNR
Median	0.09		0.04		0.08
Range	0–0.98		0–0.63		0–0.80
LODDS
Median	−2.20		−2.83		−2.36
Range	−4.84 – 3.27		−4.98 – 0.48		−5.28 – 1.30
FOBT
Negative	173	85.22	75	85.23	80	76.19
Positive	30	14.78	13	14.77	25	23.81
WBC (×10⁹/L)
Median	6.02		6.02		5.98
Range	2.37–15.01		3.08–13.97		2.90–11.76
Neut (×10⁹/L)
Median	3.25		3.54		3.60
Range	0.55–14.11		1.25–9.93		0.96–8.39
Hb (g/L)
Median	128		126		125
Range	37–166		46–155		39–158
HCT
Median	0.380		0.380		0.377
Range	0.126–0.481		0.152–0.494		0.136–0.474
PLT (× 10⁹/L)
Median	229		229		225
Range	67–676		53–620		61–617
Blood type
A	55	27.09	26	29.55	32	30.48
AB	16	7.88	6	6.82	8	7.62
B	51	25.12	18	20.45	22	20.95
O	81	39.90	38	43.18	43	40.95
ALB (g/L)
Median	39.4		38.3		38.0
Range	15.0–50.1		24.8–67.0		20.0–49.7
GLB (g/L)
Median	25.9		26.3		27.0
Range	10.0–47.0		17.6–40.0		15.8–40.4
AFP (ug/L)
Median	3.41		2.59		2.80
Range	0–1217.83		0–219.25		0–5968.13
CEA (ug/L)
Median	2.94		2.33		3.27
Range	0–465.21		0–137.51		0–314.68
CA-125 (U/mL)
Median	9.70		8.20		10.40
Range	0–251.10		0–35.80		0–118.70
CA 19–9 (U/mL)
Median	9.39		11.68		9.22
Range	0–11,134.24		0–7941.43		0–12,000
Surgical resection
Total stomach	49	24.14	19	21.59	24	22.86
Total stomach + esophagus ± other organs	135	66.50	61	69.32	71	67.62
Total stomach + other organs	19	9.36	8	9.09	10	9.52

Abbreviations: AFP α-fetoprotein, ALB albumin, CA125 cancer antigen 125, CA 19–9 cancer antigen 19–9, CEA carcino-embryonic antigen, DRM distal resection margin, FOBT fecal occult blood test, GLB globulin, Hb hemoglobin, HCT hematocrit, LNR lymph node ratio, LODDS log odds of positive lymph node, Neut neutrophil, PLN positive lymph node, PLT platelet, PRM proximal resection margin, pTNM pathological tumor node metastasis, WBC white blood cell

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us